GMAB

GENMAB A/S

GMAB·372303206·US·ADR·Healthcare - Biotechnology

GMAB (GENMAB A/S) is held by 108 institutional investors as of Q1 2026. Largest holders: Orbis Allan Gray Ltd ($346.8M), ALLIANCEBERNSTEIN L.P. ($294.4M), ARROWSTREET CAPITAL, LIMITED PARTNERSHIP ($133.5M). Net institutional sentiment: Mixed. In Q1 2026, 2 members of Congress and 60 funds bought GMAB.

108
Holders
(13 Elite)
$1.7B
Total Value
50% (121)
Consensus
60 buying - 61 selling
13F: Insider & Congress:
GMAB

Smart Money Verdict

View all
Held by 108 funds
13 elite

Who's Trading

CongressAAAlan ArmstrongBuy $1,001 - $15,000Mar 30, 2026
CongressJosh GottheimerJosh GottheimerSale $1,001 - $15,000Jan 16, 2025
CongressJosh GottheimerJosh GottheimerSale $1,001 - $15,000Dec 16, 2024
CongressJosh GottheimerJosh GottheimerBuy $1,001 - $15,000Jul 19, 2024
CongressJosh GottheimerJosh GottheimerSale $1,001 - $15,000Jun 18, 2024

Top Holders

Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Decreased
12.9M(-10.3%)$346.8M1.5%+23.39%
0
Decreased
9.6M(-12.1%)$294.4M0.1%-5.60%
0
Decreased
5M(-0.1%)$133.5M0.1%+32.16%
0
Decreased
4.5M(-1.3%)$121.7M0.0%+30.38%
0
Increased
4.4M(+26.4%)$118.4M0.2%+9.22%
44
Decreased
3.2M(-4.1%)$86.7M0.9%+1.74%
0
Increased
2.5M(+84.3%)$66M0.0%+10.26%
46
Increased
2.3M(+161.1%)$62.8M0.1%+20.68%
48
Increased
2.2M(+19.1%)$58.6M0.0%+27.81%
35
Increased
1.3M(+84.2%)$33.6M0.1%+7.72%
45
Increased
1.2M(+3792.8%)$32M0.0%+12.03%
47
Decreased
1.1M(-1.9%)$28.9M0.0%-0.76%
0
Decreased
1M(-4.3%)$27.1M0.0%+29.77%
0
Decreased
950,534(-0.7%)$25.5M0.0%+13.52%
0
Decreased
931,259(-30.1%)$25M0.0%+30.58%
0
Increased
862,301(+6.9%)$23.1M0.0%-5.95%
31
Increased
797,068(+12.2%)$21.4M0.0%+47.94%
32
Increased
792,293(+737.8%)$21.3M0.0%+13.48%
46
Increased
677,346(+1616.8%)$18.2M0.0%+12.08%
46
Increased
645,481(+27.4%)$17.3M0.0%+1.90%
35

Showing 1-20 of 127

1 / 7
GMABGMABGENMAB A/S

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used